Pharmaceutical - MAGE-A3

Filter

Current filters:

MAGE-A3

Popular Filters

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

GlaxoSmithKline’s MAGE-A3 fails in Ph III NSCLC trial

20-03-2014

There was another setback for UK pharma giant GlaxoSmithKline with its MAGE-A3 antigen specific cancer…

AgenusGlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearch

GlaxoSmithKline's cancer drug candidate fails endpoint in melanoma

05-09-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and partner US biotech firm Agenus (Nasdaq: AGEN) this morning…

AgenusBiotechnologyGlaxoSmithKlineMAGE-A3OncologyPharmaceuticalResearchVaccines

Great expectations for GlaxoSmithKline R&D newsflow

13-12-2012

Essentially, analysts at Panmure Gordon & Co anticipate a lot of pipeline newsflow from UK pharma giant…

AdvairdarapladibFinancialGlaxoSmithKlineMAGE-A3PharmaceuticalResearch

Back to top